ADMA is a useful marker, but many confounding factors should be considered! (To the Editor,)

References (1)

1. Bal UA, Yıldırır A, Aydınalp A, Kaynar G, Kanyılmaz S, Murat K, et al. Could plasma asymmetric dimethylarginine level be a novel predictor beyond the classic predictors of stent restenosis? Anadolu Kardiyol Derg 2014; 14: 491-7. [CrossRef] 2. Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59: 824–33. [CrossRef] 3. Balta S, Demirkol S, Arslan Z, Şahin MA, Yeşil FG, Küçük U. The relation between decreased glomerular filtration rate and nonvalvular atrial fibrillation. Cardiology 2013; 124: 219. [CrossRef] 4. Herzog CA. Kidney disease in cardiology. Nephrol Dial Transplant 2009; 24: 34-7. [CrossRef] 5. Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 2012; 157: 471-81. [CrossRef] 6. Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality- -an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009; 60: 481-7. [CrossRef] 7. Kurtoğlu E, Balta S, Karakuş Y, Yaşar E. Other factors ought to be kept in mind when analyzing plasma asymmetric dimethylarginine levels. Am J Hypertens 2014; 27: 500. [CrossRef]